Back to search

Switzerland· 67444001

Poteligeo 4 mg/ml, Konzentrat zur Herstellung einer Infusionslösung

A mogamulizumab product containing mogamulizumabum, registered in Switzerland by Kyowa Kirin Sàrl and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01FX09

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedPoteligeo 4 mg/ml, Konzentrat zur Her…ATCL01FX09REGISTER NO.67444001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Mogamulizumab is registered in 13 of 19 countries.

Countries holding a registration under ATC L01FX09 (mogamulizumab), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Mogamulizumab · ATC L01FX09

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of mogamulizumab costs, country by country.

Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.

  • Switzerland: $432.02 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Mogamulizumab · price per daily dose (5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$432.02
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
mogamulizumabum
Manufacturer
Kyowa Kirin Sàrl
Country
Switzerland (CH)
ATC code
L01FX09
ATC class
Mogamulizumab
Defined daily dose
5 mg, P
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680674440017
    Durchstf 1 Stk
    CHF 1433.15

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

74 interactions on record for mogamulizumab.

Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Mogamulizumab · interactions on record

74 records

  • 29 severe
  • 38 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Mogamulizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mogamulizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Poteligeo
  • Liechtenstein · Poteligeo
  • Norway · Poteligeo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4a70566d-e144-409f-b84b-0b931502a155
GET /v1/drugs/4a70566d-e144-409f-b84b-0b931502a155?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "mogamulizumabum 20 mg",
  "valid_from": "2026-03-01",
  "limitations": "[{\"description\":\"Poteligeo wird vergütet für die systemische Monotherapie von erwachsenen Patientinnen und Patienten mit histologisch bestätigter Diagnose einer rezidivierter oder refraktärer Mycosis fungoides (MF) oder Sézary-Syndrome (SS)<br>\\n• ohne large cell transformation (LCT)<br>\\n• ohne viszerale Beteiligung<br>\\ndie mindestens eine vorherige Therapie mit Methotrexat erhalten haben und unzureichend auf diese angesprochen, oder diese nicht vertragen.<br>\\nAusschliesslich für Patienten ohne allogene hämatopoetische Stammzelltransplantation in der Vorgeschichte.<br>\\nDie Behandlung mit Mogamulizumab wird bis zur Progression der Erkrankung oder einer inakzep-tablen Toxizität vergütet. Wenn nach 4 Monaten Behandlung kein Ansprechen auf Kompartiment-ebene ohne Verbesserung der Lebensqualität oder eine Gesamtprogression beobachtet wird, wird die Behandlung nicht weiter vergütet.<br>\\n<br>\\nDie Zulassungsinhaberin erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogene Packung POTELIGEO einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\n<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21341.01<br> \\n<br>\",\"costApproval\":null,\"indication\":\"21341.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-03-01\",\"validTo\":\"2029-02-28\"}]",
  "galenic_form": "Inf Konz 4 mg/ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "2023-01-01",
  "self_retention_pct": 10
}

See everything about mogamulizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.